ORLANDO, Fla. — The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Wegovy, Ozempic) reduced cardiovascular events and reduced the risk of progression to diabetes by 73%...
BASEL, SWITZERLAND — The anti-inflammatory agent colchicine failed to show significant benefit in the treatment of patients with non-cardioembolic ischemic stroke in the primary analysis of...